Every Form 4 that Tarsus Pharmaceuticals, Inc. (TARS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TARS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TARS filings page.
Tarsus Pharmaceuticals, Inc. (TARS) director David E. I. Pyott reported the settlement and exercise of 201 Restricted Stock Units, each converting into one share of common stock, on September 15, 2026. The 201 resulting shares are held indirectly through the David E. I. Pyott Trust, which now holds 9,575 common shares. Following the transaction, Pyott also holds 605 RSUs, which vest in equal installments on September 15, 2026, December 15, 2026, March 15, 2027 and June 15, 2027, subject to continuous service as a non-employee director. The filing states that 1,383 of the trust’s shares were previously held directly and transferred to the trust with no change in Pyott’s pecuniary interest, and no Rule 10b5-1 trading plan is reported.
Tarsus Pharmaceuticals, Inc. (TARS) reported that director Wendy L. Yarno exercised 302 Restricted Stock Units (RSUs) on September 15, 2026, settling them into 302 shares of common stock. The RSU award was granted for service as a non-employee director, and no Rule 10b5-1 trading plan is indicated.
After this exercise, Yarno holds 16,956 shares of common stock directly and 907 RSUs directly. Each RSU represents a contingent right to receive one share of Tarsus common stock, vesting in equal installments through June 15, 2027, subject to continuous board service.
Tarsus Pharmaceuticals, Inc. director William J. Link reported an exercise of 201 Restricted Stock Units into 201 shares of common stock on September 15, 2026, leaving 605 RSUs outstanding. On the same date he reported sales of 12,500 common shares at weighted average prices around the high-$70s under a Rule 10b5-1 trading plan adopted on September 8, 2025.
Tarsus Pharmaceuticals, Inc. (TARS) reported that President, CEO and Board Chair Bobak R. Azamian, through the Bobak Azamian Living Trust, sold a total of 10,000 shares of common stock on September 4, 2026 in transactions reported as sales in the open market or in private transactions. The sales were executed under an automatic Rule 10b5-1 trading plan adopted on December 9, 2025, at weighted average prices of about $90.27 and $91.27 per share, with individual trades in ranges from $90.00 to $90.91 and from $91.06 to $91.45. Following these transactions, he is reported to hold 33,421 shares of common stock directly.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold an aggregate of 13,953 shares of common stock on September 4, 2026. The sales included both directly held shares and shares held through a spouse’s Roth IRA, and were executed in the open market under pre-arranged Rule 10b5-1 trading plans adopted on May 29, 2026 and June 1, 2026. Following these transactions, an additional 12,040 shares of common stock are reported as indirectly held through a 401(k) plan.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Operating Officer Neervannan Seshadri sold 4,564 shares of common stock on September 4, 2026 at $85.00 per share in an open-market transaction effected under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following this sale, he directly holds 78,532 shares and is also reported with an indirect balance of 475 shares related to his daughter, for which beneficial ownership is disclaimed.
Tarsus Pharmaceuticals, Inc. (TARS) reported that President, CEO and Board Chair Bobak R. Azamian, through the Bobak Azamian Living Trust, sold 10,000 shares of common stock on September 2, 2026 in open-market transactions at a weighted average price of $80.06 per share, with individual sale prices ranging from $80.00 to $80.20.
These sales were made under an automatic Rule 10b5-1 trading plan adopted on December 9, 2025. Following the sale, the trust held 837,991 shares of Tarsus common stock, and Azamian also held 33,421 shares directly, over which he retains voting and dispositive power in the case of the trust-held shares.
Tarsus Pharmaceuticals, Inc. (TARS) reported that Chief Medical Officer Elizabeth Yeu Lin sold a total of 11,578 shares of common stock on September 1–2, 2026, at prices between $73.86 and $80.00 per share, including indirect sales through a spouse’s Roth IRA, under Rule 10b5-1 trading plans.
Goodrich Katherine reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals director Katherine Goodrich received new equity awards as part of her non-employee director compensation. She was granted 2,417 restricted stock units, each representing one share of common stock, and stock options for 3,837 shares with a strike price of $64.34. Both the RSUs and options vest in full one year after the June 25, 2026 grant date, contingent on her continued board service.
Tarsus Pharmaceuticals director Andrew D. Goldberg received new equity awards as part of his compensation for serving as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a contingent right to receive one share of Tarsus common stock. He also received a stock option covering 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option were granted in connection with the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous board service.
Tarsus Pharmaceuticals director Morrison Scott W received new equity awards tied to his service as a non-employee director. He was granted 2,417 Restricted Stock Units, each representing a right to receive one share of common stock, and 3,837 stock options to buy common stock at an exercise price of $64.34 per share.
Both the RSUs and options were granted as of the company’s 2026 annual meeting of stockholders and will vest in full on the one-year anniversary of the grant date, subject to his continuous service. Following these grants, his reported holdings in these specific RSU and option awards are 2,417 and 3,837 units, respectively.
Tarsus Pharmaceuticals, Inc. reported that director Bhaskar Chaudhuri received new equity awards as part of his compensation for serving as a non-employee director at the company’s 2026 annual meeting of stockholders. He was granted 2,417 Restricted Stock Units, each representing one share of common stock, and a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share. Both the RSUs and the option vest in full on the one-year anniversary of the June 25, 2026 grant date, subject to his continuous service on the board.
Tarsus Pharmaceuticals director Wendy L. Yarno received new equity awards as part of her non-employee director compensation for the company’s 2026 annual meeting. She was granted 1,209 and 2,417 restricted stock units, each RSU equal to one common share, plus an option for 3,837 shares at an exercise price of $64.34. The option vests in full one year after grant, while the RSUs vest either fully after one year or in four scheduled installments, all subject to continued board service. These are compensation grants, not open-market share purchases or sales.
Tarsus Pharmaceuticals director David E.I. Pyott received new equity awards tied to his service as a non-employee director at the company’s 2026 annual meeting of stockholders. The grants are compensation awards, not open-market purchases or sales.
He was granted 806 restricted stock units (RSUs) and an additional 2,417 RSUs, each representing one share of common stock. One RSU grant vests in full on the one-year anniversary of the June 25, 2026 grant date, while the other vests in four equal installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027, in each case subject to his continuous service.
Pyott also received a stock option for 3,837 shares of common stock at an exercise price of $64.34 per share, expiring on June 24, 2036. This annual option grant will vest in full on the one-year anniversary of the grant date, contingent on his continued service as a non-employee director.
Tarsus Pharmaceuticals director William J. Link, PhD reported equity awards tied to his service as a non-employee director as of the company’s 2026 annual meeting of stockholders. He received grants of restricted stock units and stock options that provide future rights to Tarsus common shares.
The filing shows 3,837 stock options with an exercise price of $64.34 per share, vesting in full on the one-year anniversary of the grant date and expiring on June 24, 2036, subject to continued service. It also reports RSU awards covering 806 and 2,417 shares, with one grant vesting in full after one year and the other vesting in four equal installments from September 15, 2026 through June 15, 2027.
Tarsus Pharmaceuticals President and CEO Bobak R. Azamian, through the Bobak Azamian Living Trust, sold a total of 10,000 shares of common stock in open-market transactions on June 17, 2026 under a pre-arranged Rule 10b5-1 trading plan. The trust continues to hold 847,991 shares indirectly, and Azamian also holds 33,421 shares directly, indicating these sales represent a small portion of his overall stake.
Tarsus Pharmaceuticals officer Jeffrey S. Farrow reported RSU vesting and a related tax transaction. On June 15, 2026, 27,881 Restricted Stock Units settled into the same number of common shares at a conversion price of $0.00 per share. On June 16, 2026, 14,396 of these shares were sold at $60.95 per share to cover tax withholding obligations under a mandatory “sell to cover” election by the company, so the sale was not a discretionary trade. After these transactions, Farrow directly owns 56,801 shares of Tarsus common stock. The RSUs were granted on April 24, 2023 and vest 25% each June 15 from 2024 through 2027, subject to his continuous service.
Tarsus Pharmaceuticals, Inc. director Katherine Goodrich reported an open-market sale of Common Stock. She sold 2,954 shares on June 15, 2026 at a price of $62.08 per share. After this transaction, she directly holds 2,233 shares of Tarsus common stock.
The filing notes that this sale was executed automatically under a pre-arranged Rule 10b5-1 trading plan adopted by Goodrich on February 27, 2026, indicating the timing was set in advance rather than decided on the trade date.
Tarsus Pharmaceuticals director William J. Link, PhD reported selling 12,500 shares of common stock in open-market transactions. On June 15, 2026, he executed two sales of 10,572 and 1,928 shares at weighted average prices of $61.97 and $62.94 per share.
The filing states these were automatic sales under a pre-arranged Rule 10b5-1 trading plan adopted on September 8, 2025, meaning the trades were scheduled in advance rather than timed discretionarily. Prices for each block were achieved across multiple trades within disclosed price ranges.
Tarsus Pharmaceuticals director Scott W. Morrison reported a routine equity compensation event. On June 12, 2026, 2,954 Restricted Stock Units (RSUs) vested and were settled into 2,954 shares of common stock at a per-share price of $0.00, reflecting a derivative exercise.
Following this settlement, Morrison directly held 7,638 shares of Tarsus common stock. He also indirectly held 6,016 shares through the Morrison-Minton Family 2004 Trust, where he serves as trustee and he and his spouse are the sole beneficiaries. No open-market purchases or sales were reported in this filing.
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals, Inc. director William J. Link, PhD received 2,954 shares of common stock through the settlement of an equal number of vested Restricted Stock Units. These RSUs were granted on June 12, 2025 for his service as a non-employee director and vested after one year. Following this automatic equity settlement, he directly holds 119,286 common shares, with no shares sold or withheld for taxes in this Form 4.
Tarsus Pharmaceuticals director Bhaskar Chaudhuri acquired 2,954 shares of Common Stock through the settlement of vested Restricted Stock Units (RSUs). These RSUs each converted into one share of common stock, a standard equity compensation event rather than an open-market trade.
Following this transaction, Chaudhuri directly holds 11,654 shares of Tarsus common stock. The derivative RSU position underlying these 2,954 shares was fully settled, with no remaining RSUs from this specific grant shown in the filing.
Tarsus Pharmaceuticals director Katherine Goodrich acquired common shares through an equity award vesting, not an open-market purchase. On June 12, 2026, 2,954 Restricted Stock Units (RSUs) settled into 2,954 shares of Tarsus common stock at a price of $0.00 per share, reflecting a compensation-related equity grant.
Following this RSU settlement, Goodrich directly owns 5,187 shares of Tarsus common stock. No shares were reported as sold or disposed of in this filing, and no tax-withholding or gifting transactions were disclosed.
Tarsus Pharmaceuticals director Wendy L. Yarno acquired 2,954 shares of common stock through the settlement of vested Restricted Stock Units (RSUs). Each RSU converted into one share of common stock, reflecting compensation for her service as a non-employee director. The RSUs were granted on June 12, 2025 and vested in full on the one-year anniversary of the grant date, subject to continuous service. Following this RSU settlement, Yarno directly holds 16,654 shares of Tarsus Pharmaceuticals common stock, and the RSU balance from this grant is now fully settled.
Tarsus Pharmaceuticals director Andrew D. Goldberg acquired 2,954 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs). The RSUs were granted on June 12, 2025 for his service as a non-employee director and vested in full one year later.
Following this compensation-related share issuance, Goldberg directly holds 19,654 shares of Tarsus common stock. The filing shows no open-market purchases or sales, only the conversion of previously granted RSUs into common shares.
Tarsus Pharmaceuticals, Inc. director David E. I. Pyott acquired common stock through equity compensation rather than open‑market trading. On April 24, 2026, 1,383 shares of common stock were issued upon settlement of vested Restricted Stock Units (RSUs), with each RSU converting into one share.
The RSUs vested in full on that date, subject to his continuous service. Following these transactions, he holds 1,383 shares directly and 7,991 shares indirectly through the David E.I. Pyott Trust.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan sold 2,989 shares of common stock in an open-market transaction at $66.75 per share on March 20, 2026. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. Following the sale, he holds 82,791 shares directly. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those shares.
Tarsus Pharmaceuticals Chief Human Resources Officer Dianne C. Whitfield reported mandated sales of common stock to cover tax withholding obligations tied to restricted stock unit vesting. Over three days, she sold a total of 12,274 shares in open-market transactions at prices between $67 and $69.42 per share. After these sales, she directly held 35,028 shares of common stock. A footnote explains the transactions were "sell to cover" sales required by the company’s tax policy and were not discretionary trades initiated by her.
Tarsus Pharmaceuticals, Inc. reported that its General Counsel, Bryan Wahl, sold a total of 12,440 shares of common stock over three days at prices between $67.00 and $69.42 per share. According to the footnote, these sales were made solely to cover tax withholding obligations tied to the vesting and settlement of restricted stock units and were mandated by the company’s sell-to-cover election, meaning they were not discretionary trades by Wahl. After these transactions, he holds 63,959 shares of Tarsus common stock directly.
Tarsus Pharmaceuticals Chief Operating Officer Seshadri Neervannan reported mandatory share sales to cover taxes tied to restricted stock vesting. On March 17–19, 2026, he sold 11,324 shares of common stock in open-market transactions at prices between $67.00 and $69.42 per share. A footnote explains these were issuer-required “sell to cover” trades for tax withholding, not discretionary sales. After the transactions, he directly holds 85,780 shares of common stock. An additional 475 shares are reported as indirectly held by his daughter, but he disclaims beneficial ownership of those securities.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported mandated stock sales tied to tax withholding on vested Restricted Stock Units. Over March 17–19, he sold a total of 13,056 shares of common stock in open-market transactions at prices around $67–$69 per share. According to the footnote, these "sell to cover" trades were required by the company to satisfy tax obligations and were not discretionary investment decisions. After these sales, Mottiwala directly holds 61,480 shares of Tarsus Pharmaceuticals common stock.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu reported mandated share sales to cover taxes from vesting restricted stock units. Over March 17–19, she sold a total of 1,144 shares of common stock in open-market transactions, including 390 shares at $67.0000 per share and 379 shares at $68.7100 per share.
According to the disclosure, these “sell to cover” trades were required under the company’s tax withholding election and were not discretionary. After the transactions, Yeu directly held 23,308 common shares, with additional indirect holdings of 6,360 shares through her spouse’s Roth IRA and 12,040 shares through a 401(k) plan.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported selling 6,430 shares of common stock in open‑market transactions over three days. He sold 2,111 shares at $69.42, 2,133 shares at $68.71, and 2,186 shares at $67.00 per share.
According to the disclosure, these sales were mandated "sell to cover" transactions to fund tax withholding obligations from vesting restricted stock units, rather than discretionary trades. After the sales, Farrow directly holds 43,316 Tarsus shares.
Tarsus Pharmaceuticals, Inc. President, CEO and Board Chair Bobak R. Azamian reported selling 34,603 shares of common stock in open-market transactions over three days at prices ranging from $67.00 to $69.42 per share. These sales were executed solely to cover tax withholding obligations tied to the vesting and settlement of restricted stock units under a mandated "sell to cover" arrangement, rather than as discretionary trades.
Following the transactions, he directly holds 33,421 common shares. He also serves as trustee of the Bobak Azamian Living Trust, which holds an additional 857,991 common shares over which he has voting and dispositive power.
Tarsus Pharmaceuticals director William J. Link, PhD sold 12,500 shares of Common Stock in open-market transactions. The sales occurred on 2026-03-16 at weighted-average prices of $68.09, $69.03, and $69.75, under an automatic Rule 10b5-1 trading plan adopted on September 8, 2025. Following these trades, he continues to hold 116,332 shares directly.
Tarsus Pharmaceuticals, Inc. Chief Human Resources Officer Dianne C. Whitfield reported the settlement of vested Restricted Stock Units into common shares. On March 15, 2026, she exercised RSUs covering 23,909 underlying shares, resulting in direct ownership of 47,302 shares of common stock.
The RSUs were granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan on March 9, 2022, March 8, 2023, March 7, 2024, and March 5, 2025. Each grant vests in four equal annual installments on March 15 of consecutive years, subject to continuous service.
Tarsus Pharmaceuticals, Inc. reported that General Counsel Bryan Wahl acquired common shares through the settlement of vested restricted stock units (RSUs). On March 15, 2026, multiple RSU awards were exercised, delivering a total of 24,236 shares of common stock at an exercise price of $0.00 per share.
Following these transactions, Wahl held 76,399 shares of Tarsus common stock directly, which includes 451 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025. The RSUs were granted between 2022 and 2025 under the 2020 Stock Plan, with 25% of each grant vesting annually on March 15, subject to continued service.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Seshadri Neervannan reported equity compensation activity tied to restricted stock units. On March 15, 2026, vested RSUs were settled into 26,287 shares of common stock at an exercise price of $0.00 per share.
The RSUs were granted under the Tarsus 2020 Stock Plan across awards from 2022 through 2025, each vesting in four annual 25% installments on March 15, subject to continuous service. After these settlements, Neervannan directly holds 97,104 shares of common stock.
The filing also shows 475 shares of common stock held indirectly by his daughter, with an explicit disclaimer that he does not beneficially own those securities for Section 16 or other purposes.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala acquired 26,482 shares of common stock on March 15, 2026 through the settlement of vested Restricted Stock Units granted under the company’s 2020 Stock Plan. Each RSU converts into one share of common stock at no cash exercise price.
Following these transactions, Mottiwala directly holds 74,536 shares of Tarsus common stock. This total includes 497 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, reflecting ongoing equity-based compensation rather than open-market buying or selling.
Tarsus Pharmaceuticals, Inc. officer Jeffrey S. Farrow reported the settlement of vested Restricted Stock Units into common stock. On March 15, 2026, he acquired 13,042 shares of common stock upon exercise/settlement of RSUs granted under the company’s 2020 Stock Plan.
The filing indicates these RSUs were from grants made on March 7, 2024 and March 5, 2025, each vesting in four equal annual installments every March 15, subject to continued service. Following these transactions, Farrow directly holds 49,746 shares of Tarsus common stock.
Tarsus Pharmaceuticals, Inc. reported that President/CEO and Board Chair Bobak R. Azamian exercised and settled restricted stock units into common shares. On March 15, 2026, he converted RSUs covering 66,274 shares of common stock at a conversion price of $0.00 per share.
After these settlements, his directly held common stock position reported in this filing is 68,024 shares. He also has an indirect holding of 857,991 common shares through the Bobak Azamian Living Trust established April 16, 2018, where he has voting and dispositive power over the shares.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu acquired shares through the vesting and settlement of Restricted Stock Units (RSUs). On March 15, 2026, 2,511 RSUs were settled into 2,511 shares of common stock at a conversion price of $0.00 per share.
Following these transactions, she held 7,534 RSUs and 24,452 shares of common stock directly. She also had indirect ownership of 6,360 common shares through a spouse’s Roth IRA and 12,040 common shares through a 401(k) plan.
According to the RSU grant terms, awarded on March 5, 2025 under the 2020 Stock Plan, 25% of the RSUs vest on March 15 of each of 2026, 2027, 2028 and 2029, subject to her continuous service.
Wahl Bryan reported acquisition or exercise transactions in this Form 4 filing.
Tarsus Pharmaceuticals General Counsel Bryan Wahl reported equity awards on March 5, 2026. He was granted stock options for 27,310 shares, with 25% vesting on March 5, 2027 and the remainder monthly over three years, and 17,161 restricted stock units vesting in four equal annual installments from March 15, 2027 to March 15, 2030, all subject to continuous service.
Tarsus Pharmaceuticals, Inc. reported that officer Jeffrey S. Farrow received equity awards consisting of a stock option for 30,724 shares and 19,306 restricted stock units, both granted at an exercise price of $0.0000 per share.
According to the grant terms, 25% of the option vests on March 5, 2027, with the remaining shares vesting in equal monthly installments over the following three years, contingent on continued service. The 19,306 RSUs vest in four equal annual installments on March 15 of each of 2027, 2028, 2029, and 2030, also subject to ongoing service.
Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala reported equity awards consisting of stock options and restricted stock units. He was granted stock options for 30,724 shares at an exercise price of $0.00, and 19,306 restricted stock units, each representing one share of common stock upon vesting.
Twenty‑five percent of the option shares vest on March 5, 2027, with the remaining options vesting monthly over three years, conditioned on continued service. The 19,306 RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, also subject to his continuous service.
Tarsus Pharmaceuticals, Inc. reported that Chief Operating Officer Neervannan Seshadri received new equity awards. On March 5, 2026, he was granted stock options for 27,310 shares at an exercise price of $0.00 per share, vesting 25% on March 5, 2027, with the remaining shares vesting monthly over three years, subject to continued service. He also received 17,161 Restricted Stock Units (RSUs), each representing one share of common stock, which vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, contingent on his continued service.
Tarsus Pharmaceuticals reported that Chief Human Resources Officer Dianne C. Whitfield received new equity awards. On March 5, 2026, she was granted stock options for 27,310 shares at an exercise price of $0.00 and 17,161 Restricted Stock Units (RSUs).
Twenty-five percent of the option shares vest on March 5, 2027, with the remainder vesting monthly over the following three years, subject to continued service. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, with each RSU representing one share of common stock upon vesting.
Tarsus Pharmaceuticals Chief Medical Officer Elizabeth Yeu reported receiving new equity awards. On March 5, 2026, she was granted stock options for 27,310 shares at an exercise price of $0.00 per share and 17,161 Restricted Stock Units.
According to the terms, 25% of the option shares vest on March 5, 2027, with the remaining option shares vesting in equal monthly installments over the following three years, subject to continuous service. The RSUs vest in four equal annual installments on March 15 of 2027, 2028, 2029, and 2030, also conditioned on her continued service.
Tarsus Pharmaceuticals reported that President, CEO and Board Chair Bobak R. Azamian received new equity awards. He was granted a stock option for 96,723 shares at an exercise price of $0.00 per share and 60,776 Restricted Stock Units, both recorded as awards rather than open-market purchases.
The option will vest 25% on March 5, 2027, with the remaining shares vesting in equal monthly installments over the next three years, subject to his continuous service. The RSUs will vest in four equal annual installments on March 15 of 2027, 2028, 2029 and 2030, also contingent on continued service.
Tarsus Pharmaceuticals, Inc. Chief Operating Officer Neervannan Seshadri sold 8,366 shares of common stock in an open-market transaction on March 4, 2026 at $76.67 per share. The sale was executed automatically under a Rule 10b5-1 trading plan adopted on November 13, 2025. After the sale, he directly held 70,817 shares. The filing also reports 475 shares held by his daughter, for which he disclaims beneficial ownership.